載入中
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
前收盤價
US$2.12
−US$0.01 · -0.47%
盤後
US$2.14
+US$0.02 · +0.94%
10月12日 下午4:00 ET
盤中時間採用ET。市場資料可能有所延遲。
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
日內區間
目前US$2.12
52週區間
目前US$2.12
盤中時間採用ET。市場資料可能有所延遲。
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
日內區間
目前US$2.12
52週區間
目前US$2.12
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 297.64萬 USD | 250.03萬 USD | 254萬 USD | 170.69萬 USD | 116.07萬 USD |
| 毛利 | 297.64萬 USD | 250.03萬 USD | 254萬 USD | 170.69萬 USD | 116.07萬 USD |
| 研究與開發 | 306.55萬 USD | 328.83萬 USD | 349.48萬 USD | 477.08萬 USD | 316.35萬 USD |
| 銷售、一般及管理費用 | 274.55萬 USD | 341.64萬 USD | 356.09萬 USD | 365.4萬 USD | 374.4萬 USD |
| 營業費用 | 581.1萬 USD | 670.47萬 USD | 705.57萬 USD | 842.48萬 USD | 690.75萬 USD |
| 利息收入 | 14.8萬 USD | 24.99萬 USD | 35.58萬 USD | 16.72萬 USD | 10.05萬 USD |
| 折舊和攤銷 | — | 15.33萬 USD | — | 2.7萬 USD | 3.55萬 USD |
| 營業利益 | −283.46萬 USD | −420.44萬 USD | −451.57萬 USD | −671.79萬 USD | −574.68萬 USD |
| 淨利 | −268.09萬 USD | −396.03萬 USD | −413.46萬 USD | −655.24萬 USD | −564.52萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2023年5月15日 | 1:10 | — | — |
股票分割 | 2019年6月25日 | 1:12 | — | — |
股票分割 | 2016年6月6日 | 1:33 | — | — |
已生效 2023年5月15日
1:10
已生效 2019年6月25日
1:12
已生效 2016年6月6日
1:33
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
